Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Barclays PLC

Barclays PLC decreased its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 7.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 127,789 shares of the biopharmaceutical company’s stock after selling 10,829 shares during the period. Barclays PLC owned approximately 0.21% of Sage Therapeutics worth $923,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. State Street Corp increased its stake in Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the period. RTW Investments LP increased its stake in Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after buying an additional 111,123 shares during the period. Erste Asset Management GmbH acquired a new position in Sage Therapeutics during the 3rd quarter valued at about $208,000. Martingale Asset Management L P increased its stake in Sage Therapeutics by 55.1% during the 3rd quarter. Martingale Asset Management L P now owns 47,077 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 16,717 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Sage Therapeutics by 52.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 70,986 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 24,356 shares during the period. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Price Performance

Shares of SAGE opened at $5.43 on Tuesday. The company has a 50-day moving average of $5.86 and a two-hundred day moving average of $7.91. The stock has a market cap of $332.17 million, a price-to-earnings ratio of -0.97 and a beta of 0.87. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Sage Therapeutics’s revenue for the quarter was up 337.1% compared to the same quarter last year. During the same period last year, the company earned ($2.81) earnings per share. Analysts anticipate that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on SAGE shares. Oppenheimer lowered their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and set a $26.00 price objective (down previously from $52.00) on shares of Sage Therapeutics in a research report on Wednesday, October 30th. Scotiabank reduced their price objective on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research report on Wednesday, October 30th. Robert W. Baird reduced their price objective on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Finally, Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective for the company in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Sage Therapeutics presently has a consensus rating of “Hold” and an average target price of $11.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.